Tumor-infiltrating lymphocytes and anti-PD-1 antibodies increase the remission rate of a variety of solid tumors

A few days ago, Iovance Biotherapeutics announced that the tumor infiltrating lymphocyte (TIL) therapy lifileucel, combined with the PD-1 inhibitor pembrolizumab (English trade name Keytruda), has been used in the treatment of multiple types of PD-1/PD that have not received PD-1/PD.

Lifileucel is based on the patient's own tumor-infiltrating lymphocytes

▲Iovance's TIL therapy production process (picture source: reference [2])

The latest clinical data show that after receiving lifileucel+pembrolizumab treatment, the remission rate (ORR) obtained by patients with multiple cancers is encouraging

The key results obtained from the test are as follows:

In cervical cancer patients: ORR was 50.

In patients with metastatic melanoma: ORR was 87.

In patients with cervical squamous cell carcinoma: ORR was 42.

The characteristics of adverse events after treatment in all cohorts were consistent with the characteristics of underlying diseases and known adverse events

In addition, in patients with advanced non-small cell lung cancer (NSCLC) who have received pretreatment, regardless of PD-L1 expression, the ORR of lifileucel treatment was 21.

Note: The original text has been deleted

Reference materials:

[1] Iovance Biotherapeutics Announces Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Multiple Solid Tumors at Society for Immunotherapy of Cancer (SITC) Annual Meeting.

[2] Iovance Corporate Presentation.